⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211394 | 0.69 | — | — | |
| SCHEMBL597404 | 0.67 | — | — | |
| SCHEMBL292333 | 0.67 | — | — | |
| SCHEMBL5561294 | 0.67 | — | — | |
| SCHEMBL24813878 | 0.65 | MAPT (0.36) | — | |
| SCHEMBL2462529 | 0.65 | MAPT (0.40) | — | |
| SCHEMBL984869 | 0.64 | — | — | |
| SCHEMBL10049904 | 0.64 | — | — | |
| SCHEMBL5541828 | 0.64 | RAB9A (0.48) | — | |
| SCHEMBL255119 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834427-B2 | Griseofulvin compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| WO-2023196975-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230303522-A1 | ARYLTETRAHYDROPYRIDAZINE DERIVATIVE OR SALT THEREOF, INSECTICIDAL AGENT CONTAINING THE COMPOUND, AND METHOD OF USE THEREOF | NIHON NOHYAKU CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | NATIONAL CANCER CENTER (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-4198029-A1 | INHIBITORS OF PEPTIDYL ARGININE DEIMINASE (PAD) ENZYMES AND USES THEREOF | University Health Network (CA) | 2023-06-21 | — | — | EP | disclosed |
| US-20230136792-A1 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND PREMATURE AGING DISORDERS | SIRTSEI PHARMACEUTICALS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230136988-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20220411416-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9586905-B2 | Benzoazepine derivative and medical use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| WO-2016189011-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-01 | — | — | WO | disclosed |
| WO-2012083170-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083164-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-2455376-A1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011159769-A2 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011156518-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2010144646-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |